ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

MSAT Director at Serán BioScience - ApplyBlast

MSAT Director

Serán BioScience

5 hours ago

3.8 on Glassdoor

Bend, Oregon, United States

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The MSAT Director leads technology transfer and product introduction for clinical and commercial manufacturing of oral solid dosage forms. This role oversees process lifecycle management, including validation, continuous improvement, and regulatory support, while collaborating with cross-functional teams to ensure operational excellence and compliance. The position involves building and leading a high-performing MSAT organization and providing strategic guidance to senior leadership.

Responsibilities

Lead technology transfer and product introduction for clinical and commercial manufacturing
Own process lifecycle management including validation strategy and continuous improvement
Build and develop high-performing MSAT organization while providing strategic updates to leadership

Skills

Qualifications

Bachelor's degree in Chemistry, Chemical Engineering, Pharmaceutical Sciences, or related field

About Serán BioScience

seranbio.com

Headquarters

Bend, Oregon, United States

Company Size

201-500 employees

Founded

2016

View Profile

Serán Bioscience is a science-driven drug development company that uses a research-first approach and advanced drug‑delivery technologies to enable and enhance clients’ medicines. They partner with biotech and pharmaceutical teams to translate therapies from concept toward clinical readiness, focusing on formulation and delivery solutions that improve patient outcomes. Headquartered in Bend, Oregon, Serán emphasizes rigorous science and collaborative development to accelerate programs and de‑risk therapeutic candidates.